DK0721778T3 - NK-1-receptorantagonister til behandling af neuronal beskadigelse og slagtilfælde - Google Patents

NK-1-receptorantagonister til behandling af neuronal beskadigelse og slagtilfælde

Info

Publication number: DK0721778T3
Authority: DK; Denmark
Prior art keywords: stroke; derivatives; neuronal damage; receptor antagonists; epilepsy
Prior art date: 1994-12-12

Application number

DK95308876T

Other languages

English (en)

Inventor

John A Lowe Iii

Robert B Nelson

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-12-12

Filing date

1995-12-07

Publication date

2004-07-12

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23394558&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0721778(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1995-12-07 Application filed by Pfizer filed Critical Pfizer

2004-07-12 Application granted granted Critical

2004-07-12 Publication of DK0721778T3 publication Critical patent/DK0721778T3/da

Links

230000003961 neuronal insult Effects 0.000 title abstract 3
102000002002 Neurokinin-1 Receptors Human genes 0.000 title abstract 2
108010040718 Neurokinin-1 Receptors Proteins 0.000 title abstract 2
239000002464 receptor antagonist Substances 0.000 title abstract 2
229940044551 receptor antagonist Drugs 0.000 title abstract 2
208000006011 Stroke Diseases 0.000 abstract 3
241000124008 Mammalia Species 0.000 abstract 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
206010015037 epilepsy Diseases 0.000 abstract 2
230000000302 ischemic effect Effects 0.000 abstract 2
238000000034 method Methods 0.000 abstract 2
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical class NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 abstract 1
206010019196 Head injury Diseases 0.000 abstract 1
206010053648 Vascular occlusion Diseases 0.000 abstract 1
206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 1
230000002490 cerebral effect Effects 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
231100000318 excitotoxic Toxicity 0.000 abstract 1
230000003492 excitotoxic effect Effects 0.000 abstract 1
208000014674 injury Diseases 0.000 abstract 1
239000002742 neurokinin 1 receptor antagonist Substances 0.000 abstract 1
150000003053 piperidines Chemical class 0.000 abstract 1
150000003235 pyrrolidines Chemical class 0.000 abstract 1
150000008584 quinuclidines Chemical class 0.000 abstract 1
210000000278 spinal cord Anatomy 0.000 abstract 1
238000001356 surgical procedure Methods 0.000 abstract 1
230000008733 trauma Effects 0.000 abstract 1
208000021331 vascular occlusion disease Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Emergency Medicine (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Vascular Medicine (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pyrrole Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Hydrogenated Pyridines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

DK95308876T 1994-12-12 1995-12-07 NK-1-receptorantagonister til behandling af neuronal beskadigelse og slagtilfælde DK0721778T3 (da)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US35470294A	1994-12-12	1994-12-12

Publications (1)

Publication Number	Publication Date
DK0721778T3 true DK0721778T3 (da)	2004-07-12

Family

ID=23394558

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK95308876T DK0721778T3 (da)	1994-12-12	1995-12-07	NK-1-receptorantagonister til behandling af neuronal beskadigelse og slagtilfælde

Country Status (16)

Country	Link
US (1)	US6376507B1 (da)
EP (1)	EP0721778B1 (da)
JP (1)	JPH08239323A (da)
KR (1)	KR100195651B1 (da)
CN (1)	CN1132072A (da)
AT (1)	ATE260656T1 (da)
AU (1)	AU719159B2 (da)
CA (1)	CA2164804C (da)
DE (1)	DE69532625T2 (da)
DK (1)	DK0721778T3 (da)
ES (1)	ES2217274T3 (da)
IL (1)	IL116249A (da)
MY (1)	MY138631A (da)
NZ (1)	NZ280627A (da)
PT (1)	PT721778E (da)
ZA (1)	ZA9510483B (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL116249A (en) *	1994-12-12	2003-07-06	Pfizer	Nk-1 receptor antagonists for the treatment of neuronal damage and stroke
CO5011067A1 (es) *	1997-11-03	2001-02-28	Novartis Ag	Derivados de bifenilo como productos farmaceuticos, su pre- paracion y composiciones farmaceuticas que los contienen
AUPQ514600A0 (en) *	2000-01-18	2000-02-10	James Cook University	Brain injury treatment
US20030083345A1 (en) *	2001-07-10	2003-05-01	Torsten Hoffmann	Method of treatment and/or prevention of brain, spinal or nerve injury
CA2568046A1 (en) *	2004-05-25	2005-12-08	Pfizer Products Inc.	3-amino-2-phenylpyrrolidine derivatives
GB0701365D0 (en) *	2007-01-24	2007-03-07	Glaxo Group Ltd	Novel pharmaceutical compositions
JP6334098B2 (ja) *	2013-06-24	2018-05-30	セイコーインスツル株式会社	表示機構、時計用ムーブメントおよび時計
WO2018175670A1 (en)	2017-03-22	2018-09-27	The Research Foundation For The State University Of New York	Matrix metalloproteinase-9 hemopexin domain inhibitors and methods of treatment using same

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX18467A (es) *	1988-11-23	1993-07-01	Pfizer	Agentes terapeuticos de quinuclidinas
DE69105131T2 (de) *	1990-06-01	1995-03-23	Pfizer	3-amino-2-arylchinuclidine, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen.
HUT62584A (en) *	1990-07-23	1993-05-28	Pfizer	Process for producing quinuclidine derivatives
AU652407B2 (en) *	1991-01-10	1994-08-25	Pfizer Inc.	N-alkyl quinuclidinium salts as substance P antagonists
WO1992015585A1 (en) *	1991-03-01	1992-09-17	Pfizer Inc.	1-azabicyclo[3.2.2]nonan-3-amine derivatives
AU657552B2 (en) *	1991-05-31	1995-03-16	Pfizer Inc.	Quinuclidine as substance P antagonists
US5527808A (en) *	1991-09-26	1996-06-18	Pfizer Inc.	Fused tricyclic nitrogen containing heterocycles
JP2656702B2 (ja) *	1992-03-23	1997-09-24	ファイザー製薬株式会社	ペプチド性キヌクリジン
WO1994004496A1 (en) *	1992-08-19	1994-03-03	Pfizer Inc.	Substituted benzylamino nitrogen containing non-aromatic heterocycles
EP1209157A1 (en) *	1993-09-17	2002-05-29	Pfizer Inc.	Heteroarylamino and heteroarylsulfonamido substituted 3-benzylaminomethyl piperidines and related compounds
EP0712778B1 (fr) *	1994-11-16	1999-04-21	Bird Sa	Cadre de cycle modulable et caractéristiques anti-vibratoires d'un tel cadre
IL116249A (en) *	1994-12-12	2003-07-06	Pfizer	Nk-1 receptor antagonists for the treatment of neuronal damage and stroke

1995
- 1995-12-04 IL IL11624995A patent/IL116249A/xx not_active IP Right Cessation
- 1995-12-05 MY MYPI95003742A patent/MY138631A/en unknown
- 1995-12-07 DE DE69532625T patent/DE69532625T2/de not_active Revoked
- 1995-12-07 AT AT95308876T patent/ATE260656T1/de not_active IP Right Cessation
- 1995-12-07 DK DK95308876T patent/DK0721778T3/da active
- 1995-12-07 PT PT95308876T patent/PT721778E/pt unknown
- 1995-12-07 ES ES95308876T patent/ES2217274T3/es not_active Expired - Lifetime
- 1995-12-07 EP EP95308876A patent/EP0721778B1/en not_active Revoked
- 1995-12-08 AU AU40304/95A patent/AU719159B2/en not_active Ceased
- 1995-12-08 CN CN95120596A patent/CN1132072A/zh active Pending
- 1995-12-08 CA CA002164804A patent/CA2164804C/en not_active Expired - Fee Related
- 1995-12-08 NZ NZ280627A patent/NZ280627A/en unknown
- 1995-12-09 KR KR1019950048062A patent/KR100195651B1/ko not_active Expired - Fee Related
- 1995-12-11 ZA ZA9510483A patent/ZA9510483B/xx unknown
- 1995-12-12 JP JP7323355A patent/JPH08239323A/ja active Pending
1998
- 1998-06-18 US US09/099,289 patent/US6376507B1/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
DE69532625D1 (de)	2004-04-08
JPH08239323A (ja)	1996-09-17
MY138631A (en)	2009-07-31
ES2217274T3 (es)	2004-11-01
CN1132072A (zh)	1996-10-02
DE69532625T2 (de)	2005-02-03
AU4030495A (en)	1996-06-20
CA2164804A1 (en)	1996-06-13
US6376507B1 (en)	2002-04-23
IL116249A (en)	2003-07-06
EP0721778A2 (en)	1996-07-17
ATE260656T1 (de)	2004-03-15
AU719159B2 (en)	2000-05-04
IL116249A0 (en)	1996-03-31
NZ280627A (en)	2000-06-23
EP0721778A3 (en)	1999-11-10
KR960021025A (ko)	1996-07-18
PT721778E (pt)	2004-07-30
EP0721778B1 (en)	2004-03-03
CA2164804C (en)	1999-07-27
KR100195651B1 (ko)	1999-06-15
ZA9510483B (en)	1997-06-09

Publication	Publication Date	Title
EP0686629A3 (en)	1999-02-10	Cyclohexyl tachykinine receptor antagonists
EP0722737A4 (en)	1999-04-28	MEDICINE AGAINST THE CRANIAL NERVAN
DK1196397T3 (da)	2006-01-02	Metabotrope glutamatreceptorantagonister og anvendelse deraf til behandling af sygdomme i centralnervesystemet
BR0200283A (pt)	2002-10-08	Composições farmacêuticas para o tratamento de distúrbios do snc e de outros distúrbios
ATE231145T1 (de)	2003-02-15	Nichtpeptidische tachykinin-rezeptor-antagonisten
SE9303335L (sv)	1995-04-13	Ändsektion av rambalk
IL114683A0 (en)	1995-11-27	Combination treatment for inhibiting bone loss
ATE426405T1 (de)	2009-04-15	Amino-substituierte diarylaa,ducyclohepten- analoga als muscarinische agonisten und verfahren zur behandlung von neuropsychiatrischen erkrankungen
DK0721778T3 (da)	2004-07-12	NK-1-receptorantagonister til behandling af neuronal beskadigelse og slagtilfælde
WO1996022990A3 (en)	1996-10-10	Aza and aza (n-oxy) analogs of glycine/nmda receptor antagonists
AU1463792A (en)	1992-10-06	N-substituted (alpha-imidazolyl-toluyl) pyrrole angiotensin ii antagonists for treatment of circulatory disorders
ATE325610T1 (de)	2006-06-15	Xanthinderivative zur behandlung von hirnischämie
DE69432626D1 (de)	2003-06-12	Melatonin-Derivate zur Verwendung in der Behandlung von Desynchronisierungs-Erkankungen
PL297472A1 (en)	1994-01-24	Benzimidazoles, therapeutic agents containing such compounds and method of obtaining them
ATE256126T1 (de)	2003-12-15	5-heteroatom-alkyl substituierte 3-oxo-pyrido(1,2-a)benzimidazol-4-carboxamid derivate zur behandlung zentral nervöser system störungen
ATE161856T1 (de)	1998-01-15	Verfahren zum thermomechanischen abbau von polyolefinen
WO2002076437A3 (en)	2003-02-20	Methods for treating neurodegenerative diseases including alzheimer's
DE69800906D1 (de)	2001-07-19	Verwendung von Olanzapine zur Herstellung eines Arzneimittels zur Behandlung der zerebralen fokalen Ischämie
ITMI920106A1 (it)	1993-07-22	Composizioni farmaceutiche comprendenti melatonina o un suo derivato-agonista, atte al trattamento dei disordini cerebro-vascolari
BG105289A (en)	2001-11-30	The use of r(+)-alpha-(2,3-dimethoxyphenyl)-1-[2- (4-fluorophenyl)ethyl]-4-pip eridinemethanol for the treatment of sleep disorders
ZA971323B (en)	1997-08-27	Novel substituted N-methyl-N-(4-(4-(1H-benzimidazol-2-yl-amino)piperidin 1-yl)-2-(aryl)butyl)benzamides useful for the treatment of allergic diseases.
RU93035807A (ru)	1997-02-27	Способ лечения юношеского эпифизиолиса